医改新政策下辽宁省肿瘤医院新型抗肿瘤药物使用情况分析  

Analysis on the application of novel antineoplastic drugs in Liaoning Cancer Hospital and Institute under the new policy of medical reform

作　　者：王宇 刘广宣 WANG Yu;LIU Guang-xuan(Department of Pharmacy,Cancer Hospital of China Medical University,Liaoning Cancer Hospital and Institute,Shenyang 110042,China)

机构地区：[1]中国医科大学肿瘤医院辽宁省肿瘤医院药学部,辽宁沈阳110042

出　　处：《现代药物与临床》2022年第4期869-875,共7页Drugs & Clinic

摘　　要：目的分析医改新政策下辽宁省肿瘤医院新型抗肿瘤药物的使用情况,为规范其管理及合理应用提供参考。方法运用药物经济学的金额分析法和用药频度(DDDs)分析法对2018—2021年辽宁省肿瘤医院新型抗肿瘤药物的使用数据进行统计分析。结果医改新政策下,新型抗肿瘤药物品种逐年增加,2019年销售金额和构成比激增,之后呈平稳趋势。大多数药物DDDs逐年上升,限定日费用(DDC)下降的药物近50%,两者前10位排序均变化不大,药品销售金额排序(B)/DDDs排序(A)大于0.90的药物比例基本恒定(70%~80%)。结论医院新型抗肿瘤药的使用基本合理。伴随医改新政策的实施,新型抗肿瘤药物品种增多、价格降低,患者受益的同时也应对其使用加强监管。Objective To investigate the application of novel antineoplastic drugs in Liaoning Cancer Hospital and Institute under the new policy of medical reform,and provide references for standardizing the management and rational application.Methods The data of novel antineoplastic drugs in Liaoning Cancer Hospital and Institute from 2018 to 2021 were calculated and analyzed by using defined daily cost(DDC)analysis of pharmacoeconomics and defined daily dose system(DDDs)analysis.Results Under new medical reform policies,the variety of novel antineoplastic drugs increased year by year.Consumption sum and constituent ratio increased sharply in 2019,and then the trend was stable.The DDDs of most drugs increased year by year.DDC of nearly half of the drugs decreased,while there was little change in the top 10 ranking of DDDs and DDC.The proportion of drugs with ratio of sequence of consumption sum(B)/sequence of DDDs(A)greater than 0.90 was basically constant,accounting for 70%—80%.Conclusion The utilization of novel antineoplastic drugs in our hospital is basically reasonable.With the implementation of new medical reform policies,the variety of novel antineoplastic drugs has increased and the price has decreased,which is benefit for patients.But the supervision of the usage still need to be strengthened.

关 键 词：医改新政策 新型抗肿瘤药物 销售金额 用药频度 限定日费用 排序比 

分 类 号：R979.1[医药卫生—药品]